Over the past decades, considerable progress has been made in the pharmacological treatment of immune-mediated joint diseases such as rheumatoid arthritis and psoriatic arthritis; however, treatment-resistant arthritis remains a major clinical challenge. To tackle insufficient treatment outcomes, further research into the underlying mechanisms and patterns of non-responsiveness is needed.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Location and amount of joint involvement differentiates rheumatoid arthritis into different clinical subsets
npj Digital Medicine Open Access 23 October 2025
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Ciurea, A. et al. Differences in the response to TNF inhibitors at distinct joint locations in patients with PsA: results from nine registries. Arthritis Res. Ther. 27, 18 (2025).
Stekhoven, D. et al. Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. Clin. Rheumatol. 36, 2035–2043 (2017).
Ciurea, A. et al. Joint-specific responses to tofacitinib and adalimumab in patients with psoriatic arthritis: post hoc analysis of a phase 3 study. Arthritis Rheumatol. 73 (Suppl. 9), abstr. 1349 (2021).
Ciurea, A. et al. Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start. Arthritis Res. Ther. 25, 185 (2023).
Heckert, S. L. et al. Joint inflammation tends to recur in the same joints during the rheumatoid arthritis disease course. Ann. Rheum. Dis. 81, 169–174 (2022).
Ejeskar, A. & Ortengren, R. Isolated finger flexion force: a methodological study. Hand 13, 223–230 (1981).
Elhai, M. et al. The long non-coding RNA HOTAIR contributes to joint-specific gene expression in rheumatoid arthritis. Nat. Commun. 14, 8172 (2023).
Ciurea, A. et al. Joint-specific responses to tofacitinib and adalimumab in rheumatoid arthritis: a post hoc analysis of data from ORAL Standard and ORAL Strategy. Ann. Rheum. Dis. 78 (Suppl. 2), abstr. FRI0144 (2019).
Maarseveen, T. D. et al. Location of joint involvement differentiate rheumatoid arthritis into different clinical subsets. Preprint at medRxiv https://doi.org/10.1101/2023.09.19.23295482 (2023).
Wechalekar, M. D. et al. Active foot synovitis in patients with rheumatoid arthritis: unstable remission status, radiographic progression, and worse functional outcomes in patients with foot synovitis in apparent remission. Arthritis Care Res. 68, 1616–1623 (2016).
Acknowledgements
We would like to thank our teams and collaborators and specifically R. Micheroli and A. Steimer for the ongoing discussions on the site-specificity of treatment responses.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Ciurea, A., Ospelt, C. Location-specific treatment of chronic inflammatory joint disease. Nat Rev Rheumatol 21, 507–508 (2025). https://doi.org/10.1038/s41584-025-01278-x
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41584-025-01278-x
This article is cited by
-
Advances in AI-based patient stratification for rheumatic diseases
Nature Reviews Rheumatology (2025)
-
Location and amount of joint involvement differentiates rheumatoid arthritis into different clinical subsets
npj Digital Medicine (2025)
